Novel Therapies in Advanced Renal Cell Carcinoma – Management of Adverse Events from Sorafenib and Sunitinib: Addition [PDF]
, 2008 Frank Meyer
openalex +1 more source
Observational Study of Tocilizumab in Children With Febrile Infection‐Related Epilepsy Syndrome
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective This study aimed to assess the efficacy and safety of using tocilizumab in children with febrile infection‐related epilepsy syndrome (FIRES) and explore tocilizumab‐related changes in interleukin (IL)‐6 levels. Methods Patients with FIRES admitted to the Intensive Care Unit (ICU) of Beijing Children's Hospital were retrospectively ...
Yushan He +7 more
wiley +1 more source
An mHealth app technology to strengthen adverse event management of multi-drug-resistant tuberculosis in Vietnam: Protocol for a process evaluation of the V-SMART trial. [PDF]
Trop Med Int HealthNguyen BH +15 more
europepmc +1 more source
Update on Sideline and Event Preparation for Management of Sudden Cardiac Arrest in Athletes
, 2007 Kimberly G. Harmon, Jonathan A. Drezner
openalex +1 more source
Clinical Characteristics of Parkinsonism in HTLV‐1‐Associated Myelopathy
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Human T‐lymphotropic virus type 1 (HTLV‐1)‐associated myelopathy/tropical spastic paraparesis (HAM/TSP) is the classic neurological manifestation of HTLV‐1 infection; however, this virus has also been associated with other neurological disorders. Concurrent parkinsonism is relatively rare and presents diagnostic challenges.
Mika Dozono +8 more
wiley +1 more source
Immunotherapy for renal cell carcinoma: New therapeutic combinations and adverse event management strategies: A review. [PDF]
Medicine (Baltimore)Ma X +6 more
europepmc +1 more source
A COLOURED PETRI NET APPROACH FOR THE MANAGEMENT OF OPERATING MODES IN DISCRETE EVENT SYSTEMS
, 2007 Belhassen Zouari +2 more
openalex +1 more source
Existing and future standards for event-driven business process management [PDF]
, 2009 Rainer von Ammon +5 more
openalex +1 more source
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Background Sphingosine‐1‐phosphate receptor modulators (S1PRM) are used to treat relapsing multiple sclerosis (MS). Each drug has a different S1PR‐subtype selectivity. They target the G‐protein coupled S1P receptors and exert significant immunomodulatory effects, such as preventing the formation of new CNS lesions and the reactivation of pre ...
Faizan Shahzad +8 more
wiley +1 more source